January 29, 2018 / 12:05 PM / 22 days ago

BRIEF-Prometic's Pbi-4050 Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis Finalized

Jan 29 (Reuters) - Prometic Life Sciences Inc:

* PROMETIC‘S PBI-4050: PHASE 3 PIVOTAL CLINICAL TRIAL DESIGN FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) FINALIZED

* PROMETIC LIFE SCIENCES - BASED ON RECOMMENDATIONS FROM FDA, CO NOW WILL UNDERTAKE AN “ALL COMERS STUDY”

* PROMETIC - PBI-4050 STUDY WILL ENROLL PATIENTS WITH MILD-TO-MODERATE IPF, REGARDLESS OF BACKGROUND STANDARD OF CARE WITH NINTEDANIB OR NOT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below